Hospital
Norton Scott Hospital, LLC
Norton Scott Hospital, LLC was paid $9.17M by Medicaid between Jan 2018 and Nov 2024, across 84 billing codes. Its largest line is 99283, emergency room visit (moderate) — 37% of everything it billed.
33Billing provider infoNORTON SCOTT HOSPITAL, LLC
SCOTTSBURG, IN 47170
SCOTTSBURG, IN 47170
33aNPI1013251594assigned 11/21/2012
33bProvider typeCritical Access Hospital
28Total paid$9.17M
24GClaims249,396
24DCodes billed84
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other Critical Access Hospital providers in Indiana
Rank by total paid#2 of 26
Median peer was paid$4.16M
This provider vs. median2.2×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official GAST, SHELLEY controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 34,710 | $468K | |
| 2019 | 30,498 | $933K | |
| 2020 | 26,835 | $920K | |
| 2021 | 36,401 | $1.42M | |
| 2022 | 51,129 | $2.00M | |
| 2023 | 43,981 | $2.01M | |
| 2024incomplete | 25,842 | $1.42M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 37% | 23,819 | 20,217 | $3.40M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 10% | 9,440 | 7,608 | $933K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 9.7% | 10,873 | 8,140 | $889K |
| 71045 | Radiologic examination, chest; single view | 7.5% | 7,481 | 5,471 | $691K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 5.3% | 9,686 | 6,674 | $490K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 3.9% | 2,384 | 2,094 | $355K |
| G0378 | Hospital observation service, per hour | 3.0% | 3,455 | 1,294 | $279K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 3.0% | 5,885 | 4,840 | $274K |
| 96361 | Intravenous infusion, hydration; each additional hour | 2.4% | 3,800 | 1,858 | $219K |
| 87428 | 2.0% | 10,163 | 8,117 | $180K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.7% | 4,194 | 3,241 | $157K |
| 80053 | Comprehensive metabolic panel | 1.7% | 27,013 | 19,565 | $154K |
72 more codes
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.5% | 1,863 | $133K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.4% | 27,943 | $125K |
| 71046 | Radiologic examination, chest; 2 views | 1.3% | 1,245 | $115K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 1.2% | 934 | $107K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 1.0% | 711 | $93K |
| 36415 | Collection of venous blood by venipuncture | <1% | 32,201 | $78K |
| 84484 | <1% | 7,914 | $61K | |
| 87650 | <1% | 3,507 | $38K | |
| 80306 | <1% | 4,320 | $38K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 940 | $33K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 814 | $32K |
| 86403 | <1% | 5,132 | $32K | |
| 81001 | <1% | 9,739 | $25K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 2,105 | $23K |
| 83735 | <1% | 4,281 | $20K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 2,577 | $19K |
| 76376 | <1% | 919 | $19K | |
| 80061 | Lipid panel | <1% | 2,562 | $15K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 493 | $15K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 3,212 | $14K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,283 | $10K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 427 | $9K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 164 | $9K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 690 | $8K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 19 | $7K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 154 | $7K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 245 | $6K |
| 87040 | <1% | 572 | $6K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 1,389 | $5K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 178 | $5K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 448 | $5K |
| 81025 | <1% | 964 | $4K | |
| 81003 | <1% | 1,361 | $4K | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 42 | $4K |
| 83880 | <1% | 260 | $3K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 763 | $3K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 13 | $3K |
| 83690 | <1% | 453 | $2K | |
| 84439 | <1% | 477 | $2K | |
| 86756 | <1% | 320 | $2K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 98 | $2K |
| 82948 | <1% | 346 | $2K | |
| 83605 | <1% | 149 | $1K | |
| 94762 | <1% | 33 | $1K | |
| 96376 | <1% | 490 | $856.17 | |
| 84436 | <1% | 124 | $532.09 | |
| 85730 | <1% | 128 | $365.87 | |
| 84703 | <1% | 82 | $362.56 | |
| 85379 | <1% | 46 | $291.53 | |
| 85610 | <1% | 129 | $282.73 | |
| 82550 | <1% | 155 | $269.51 | |
| 96367 | <1% | 16 | $242.52 | |
| 85027 | <1% | 43 | $231.68 | |
| 84481 | <1% | 17 | $197.16 | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 16 | $186.70 |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 16 | $186.70 |
| 82150 | <1% | 32 | $148.47 | |
| 83970 | <1% | 13 | $148.29 | |
| 87070 | <1% | 34 | $142.10 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 131 | $125.89 |
| J3490 | Unclassified drugs | <1% | 67 | $76.08 |
| 82570 | <1% | 42 | $41.34 | |
| 82043 | <1% | 16 | $17.34 | |
| 84100 | <1% | 13 | $17.01 | |
| 84156 | <1% | 12 | $5.14 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 1,549 | $0.13 |
| J7120 | Ringers lactate infusion, up to 1000 cc | 0% | 318 | $0.00 |
| J2550 | Injection, promethazine hcl, up to 50 mg | 0% | 17 | $0.00 |
| Q9962 | High osmolar contrast material, 300-349 mg/ml iodine concentration, per ml | 0% | 32 | $0.00 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 0% | 31 | $0.00 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | 0% | 3,016 | $0.00 |
| A9270 | Non-covered item or service | 0% | 358 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialGAST, SHELLEY (VP MANAGED CARE)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.